A Phase 4 interventional study of Dexamethasone 0.1% ophthalmic suspension and Olopatadine hydrochloride 0.1% ophthalmic solution in Allergic Conjunctivitis, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-02-28.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing olopatadine in Conjunctivitis, Allergic — none open to participants now, none under way, none of them phase 3. olopatadine · Conjunctivitis, Allergic.
Among the 27 studies testing olopatadine in Conjunctivitis, Allergic, this one is the 9th largest by enrollment, is one of 7 that started in 2010, is one of 16 in phase 4, and was the 11th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →None of the 27 studies testing olopatadine in Conjunctivitis, Allergic is open now. The open studies under Conjunctivitis, Allergic, anywhere →
olopatadine: first FDA approval 1996 (PATADAY TWICE DAILY RELIEF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 61 across the 27 interventional studies. Of the 26 that completed or were terminated, 14 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 27 have an industry lead sponsor. The 8 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
21 studies in Conjunctivitis, Allergic by Alcon: none open now, none under way, none of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 21 studies in Conjunctivitis, Allergic by Alcon, this one is the 11th largest by enrollment, is one of 6 that started in 2010, is one of 10 in phase 4, and was the 9th registered.
Alcon’s Conjunctivitis, Allergic studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing olopatadine in Conjunctivitis, Allergic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 21 in Conjunctivitis, Allergic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
This study consisted of 6 visits. Visit 1 was the Medical Screening Visit (skin prick test). Visit 2 and Visit 3 consisted of 2 consecutive EEC Visits (3 hours in the EEC followed by 7 hours in the Clinic, 10 hours total, each visit) followed by 7 days of wash-out. Visit 2 and Visit 3 occurred prior to dispense and the measures obtained during these visits were used as baseline. At Visit 4 patients were randomized and dispensed the assigned study medication for 7 days of at-home dosing. Visit 5 (Day 8 of treatment) and Visit 6 (Day 9 of treatment) consisted of 2 additional consecutive EEC Visits (3 hours in the EEC followed by 7 hours in the clinic, 10 hours total, each visit). During each EEC visit, patients were exposed to either ragweed or cat allergen, depending on their skin prick test results. Of the 180 participants enrolled, 170 received at least one dose of study treatment and were randomized to one of the three study treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dexamethasone 0.1% ophthalmic suspension, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days \[Visit 4 through Visit 6 morning only\]
Drug: Dexamethasone 0.1% ophthalmic suspension
Olopatadine hydrochloride 0.1% ophthalmic solution, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days \[Visit 4 through Visit 6 morning only\]
Drug: Olopatadine hydrochloride 0.1% ophthalmic solution
Inactive ingredients, used as placebo, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days \[Visit 4 through Visit 6 morning only\]
Other: Inactive ingredients, used as placebo
Maxidex
Patanol
Tears Naturale II
Mean Change From Baseline in Staff-Assessed Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)], Maxidex and Placebo
Ocular redness ratings were collected for nasal and temporal areas of each eye and scored on a scale from 0 (none) to 4 (extremely severe), 0.5 unit steps permitted. The AUC computation was based on peak redness score (maximum of four areas of redness) at each time point (pre-treatment, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3 hours in the EEC and 3.5, 4, 5, 6, 7, 8, 9, 10 hours in the Clinic). The patient was dosed AM 30 minutes prior to entering the EEC (Visit 6). This outcome measure evaluates a late-phase effect, for which Maxidex vs. Placebo is the meaningful comparison.
Time frame: Baseline (Visit 3, pre-treatment); Visit 6 (Day 9 of treatment)
Mean Change From Baseline Patient-Assessed Ocular Itching, Area Under the Curve From Time Zero to Hour 3 [AUC (0-3)], Patanol and Placebo
Ocular itching was scored a scale from 0 (none) to 4 (incapacitating itch with irresistible urge to rub) in 0.5 unit steps. The AUC computation was based on the score at each time point (pre-treatment, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, and 3 hours in the EEC). The patient was dosed AM 30 minutes prior to entering the EEC (Visit 5). This outcome measure evaluates an early-phase effect, for which Patanol vs. Placebo is the meaningful comparison.
Time frame: Baseline (Visit 2, pre-treatment), Visit 5 (Day 8 of treatment)
Patients were recruited from one study center in Canada.
| Milestone | Maxidex/Ragweed Allergic | Patanol/Ragweed Allergic | Tears Naturale II/Ragweed Allergic | Maxidex/Cat Allergic | Patanol/Cat Allergic | Tears Naturale II/Cat Allergic |
|---|---|---|---|---|---|---|
| Started | 26 | 24 | 26 | 31 | 31 | 32 |
| Completed | 26 | 24 | 24 | 29 | 30 | 32 |
| Not completed | 0 | 0 | 2 | 2 | 1 | 0 |
| Withdrew: Patient decision, not related to ae | 0 | 0 | 2 | 2 | 1 | 0 |
Ocular redness ratings were collected for nasal and temporal areas of each eye and scored on a scale from 0 (none) to 4 (extremely severe), 0.5 unit steps permitted. The AUC computation was based on peak redness score (maximum of four areas of redness) at each time point (pre-treatment, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3 hours in the EEC and 3.5, 4, 5, 6, 7, 8, 9, 10 hours in the Clinic). The patient was dosed AM 30 minutes prior to entering the EEC (Visit 6). This outcome measure evaluates a late-phase effect, for which Maxidex vs. Placebo is the meaningful comparison.
| hours x units on a scale | Maxidex/Ragweed Allergic | Tears Naturale II/Ragweed Allergic | Maxidex/Cat Allergic | Tears Naturale II/Cat Allergic |
|---|---|---|---|---|
| Baseline (Visit 3, pre-treatment) | 18.120 ± 6.260 | 19.362 ± 7.666 | 16.823 ± 5.530 | 17.572 ± 6.803 |
| Visit 6 (Day 9 of treatment) | 11.671 ± 5.983 | 15.786 ± 6.514 | 11.313 ± 3.943 | 13.824 ± 4.792 |
| Change | -6.450 ± 7.002 | -3.576 ± 6.959 | -5.511 ± 5.916 | -3.748 ± 6.351 |
Ocular itching was scored a scale from 0 (none) to 4 (incapacitating itch with irresistible urge to rub) in 0.5 unit steps. The AUC computation was based on the score at each time point (pre-treatment, 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, and 3 hours in the EEC). The patient was dosed AM 30 minutes prior to entering the EEC (Visit 5). This outcome measure evaluates an early-phase effect, for which Patanol vs. Placebo is the meaningful comparison.
| hours x units on a scale | Patanol/Ragweed Allergic | Tears Naturale II/Ragweed Allergic | Patanol/Cat Allergic | Tears Naturale II/Cat Allergic |
|---|---|---|---|---|
| Baseline (Visit 2, pre-treatment) | 4.776 ± 1.759 | 5.669 ± 2.062 | 5.904 ± 2.224 | 5.654 ± 2.408 |
| Visit 5 (Day 8 of treatment) | 2.630 ± 1.877 | 3.990 ± 2.781 | 2.881 ± 2.203 | 2.586 ± 2.181 |
| Change | -2.146 ± 1.913 | -1.680 ± 2.065 | -3.023 ± 2.668 | -3.068 ± 2.361 |
Collected over Adverse events were collected for the duration of the study (5 months, 29 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maxidex | — | 0/57 (0%) | 13/57 (22.8%) |
| Patanol | — | 0/55 (0%) | 7/55 (12.7%) |
| Tears Naturale II | — | 0/58 (0%) | 7/58 (12.1%) |
| Event | Maxidex | Patanol | Tears Naturale II |
|---|---|---|---|
| Eye painEye disorders | 5/57 | 0/55 | 0/58 |
| Eye irritationEye disorders | 4/57 | 4/55 | 4/58 |
| HeadacheNervous system disorders | 4/57 | 3/55 | 3/58 |
| Age, Continuous(years) | Maxidex/Ragweed Allergic | Patanol/Ragweed Allergic | Tears Naturale II/Ragweed Allergic | Maxidex/Cat Allergic | Patanol/Cat Allergic | Tears Naturale II/Cat Allergic | Total |
|---|---|---|---|---|---|---|---|
| Mean | 34.0 ± 9.6 | 39.2 ± 13.8 | 40.0 ± 10.0 | 34.5 ± 11.6 | 32.9 ± 9.3 | 35.9 ± 8.4 | 35.91 ± 10.62 |
| Sex: Female, Male(Participants) | Maxidex/Ragweed Allergic | Patanol/Ragweed Allergic | Tears Naturale II/Ragweed Allergic | Maxidex/Cat Allergic | Patanol/Cat Allergic | Tears Naturale II/Cat Allergic | Total |
|---|---|---|---|---|---|---|---|
| Female | 11 | 13 | 17 | 23 | 22 | 24 | 110 |
| Male | 15 | 11 | 9 | 8 | 9 | 8 | 60 |
| Region of Enrollment(participants) | Maxidex/Ragweed Allergic | Patanol/Ragweed Allergic | Tears Naturale II/Ragweed Allergic | Maxidex/Cat Allergic | Patanol/Cat Allergic | Tears Naturale II/Cat Allergic | Total |
|---|---|---|---|---|---|---|---|
| Canada | 26 | 24 | 26 | 31 | 31 | 32 | 170 |
The record gives a start of Mar 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Olopatadine